CCL3 and breast cancer: Our findings provide possibilities to extend PARP inhibitors for the treatment of BRCA-WT breast cancer patients or PARP inhibitor-resistant patients through cotreatment of CCL3, β-catenin inhibitors, anti-RANKL antibody, or bisphosphonates.